LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on the thalassemia market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat thalassemia.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING
Thalassemia: Market overview
Thalassemia is an inherited blood disorder in which the body produces an abnormal form of hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen. The disorder can lead to the excessive destruction of red blood cells, thereby causing anemia. Thalassemia can be inherited from one parent or both the parents.
According to a senior market research analyst at Technavio, “Thalassemia is of two types, namely alpha-thalassemia and beta-thalassemia. Alpha-thalassemia occurs when there is a loss of two of the four alpha globin gene therapy variants from the body. Beta-thalassemia occurs when there is a decrease in the production of hemoglobin in the body.”
Thalassemia: Segmentation analysis
This market research report segments the thalassemia market based on therapies employed (monotherapy and monotherapy/combination therapy), RoA (oral, intravenous, subcutaneous, intraosseous, and unknown), therapeutic modality (gene therapy, small molecule, protein, biological, plant-derived, and unknown), targets for drugs under development (HSCs, HbF, TGF-beta proteins, TMPRSS6, HDAC1/2, glycine reuptake, hepcidin, iron, ferroportin, pyruvate kinase, and iron homeostatis), MoA (HbF stimulator, TGF-beta protein regulator, TMPRSS6 inhibitor, glycine reuptake inhibitor, iron chelator, hepcidin stimulator, ferroportin stimulator, pyruvate kinase stimulator, cell replacement, gene transfer, T lymphocyte replacement, and iron homeostatis), and recruitment status (recruiting and active, not yet recruiting).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 69% of the molecules that are being investigated for the treatment of thalassemia are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About 24.15% of the total molecules that are in the current pipeline are expected to be administered orally.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
- Recruitment volume
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
